---
document_datetime: 2025-11-11 11:32:51
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/norvir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: norvir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5052021
conversion_datetime: 2025-12-22 12:29:44.079824
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Norvir

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type II /  | This was an application for a group of | 18/09/2025                          | 03/11/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Norvir-H-C- |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249795   | variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 000127-II-EMA/VR/0000249795   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
|                     | C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted B.II.f.1.a Reduction of the shelf life of the finished product - B.II.f.1.a.1 As packaged for sale - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted A grouped application consisting of: Type II (C.I.6.a): To modify the approved therapeutic indication to reflect current clinical use as a pharmacokinetic enhancer of other antiretroviral products only. Consequently, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.8 and 5.1 of the SmPC and the Package Leaflet are updated accordingly. The updated RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI. Type IB (B.II.f.1.a.1): To reduce the shelf life of Norvir 100 mg powder for oral suspension as packaged for sale, from 36 months to 18 months and to reduce the |                               |

<div style=\"page-break-after: always\"></div>

| from 2 years to 18 months. Type IB (B.II.f.1.e): To change the stability protocol of Norvir 100 mg powder for oral suspension to reflect updated long term testing intervals as a consequence of the reduction in shelf life. The group of variations leads to amendments to the annexes I and IIIB, and to the RMP.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|